MX2023003792A - Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. - Google Patents
Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.Info
- Publication number
- MX2023003792A MX2023003792A MX2023003792A MX2023003792A MX2023003792A MX 2023003792 A MX2023003792 A MX 2023003792A MX 2023003792 A MX2023003792 A MX 2023003792A MX 2023003792 A MX2023003792 A MX 2023003792A MX 2023003792 A MX2023003792 A MX 2023003792A
- Authority
- MX
- Mexico
- Prior art keywords
- chloroquine
- treatment
- inflammatory
- clemizole
- cancerous conditions
- Prior art date
Links
- 229960003677 chloroquine Drugs 0.000 title abstract 3
- CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical class C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 title abstract 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 title 1
- 229950002020 clemizole Drugs 0.000 abstract 2
- 201000007270 liver cancer Diseases 0.000 abstract 2
- 208000014018 liver neoplasm Diseases 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen en la presente métodos para uso de R-cloroquina o clemizol o combinaciones de R-cloroquina y clemizol para el tratamiento de un sujeto que necesita del mismo. Los métodos incluyen métodos de tratamiento de afecciones inflamatorias, tratamiento de cáncer hepático o reducción del riesgo de desarrollar cáncer hepático en un sujeto. Los usos también incluyen métodos de tratamiento de esteatohepatitis no alcohólica en un sujeto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562187061P | 2015-06-30 | 2015-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023003792A true MX2023003792A (es) | 2023-04-26 |
Family
ID=57609247
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016681A MX2017016681A (es) | 2015-06-30 | 2016-06-30 | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. |
MX2023003792A MX2023003792A (es) | 2015-06-30 | 2017-12-18 | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. |
MX2022008100A MX2022008100A (es) | 2015-06-30 | 2017-12-18 | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016681A MX2017016681A (es) | 2015-06-30 | 2016-06-30 | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022008100A MX2022008100A (es) | 2015-06-30 | 2017-12-18 | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. |
Country Status (13)
Country | Link |
---|---|
US (2) | US10688083B2 (es) |
EP (1) | EP3317274A4 (es) |
JP (3) | JP7068827B2 (es) |
KR (2) | KR20180032578A (es) |
CN (2) | CN107922404B (es) |
AU (3) | AU2016288699B2 (es) |
CA (2) | CA2989634C (es) |
HK (1) | HK1249508A1 (es) |
IL (4) | IL310969A (es) |
MX (3) | MX2017016681A (es) |
TW (3) | TW202402283A (es) |
WO (1) | WO2017004454A1 (es) |
ZA (1) | ZA201708471B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016288699B2 (en) * | 2015-06-30 | 2020-11-26 | Eiger Group International, Inc. | Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions |
CN106831571A (zh) * | 2017-02-13 | 2017-06-13 | 中卫市创科知识产权投资有限公司 | 一种硫酸氯喹生产工艺 |
EP3710831A4 (en) * | 2017-11-15 | 2022-01-12 | Beth Israel Deaconess Medical Center, Inc. | MARKERS FOR THE DIAGNOSIS AND TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED HEPATIC FIBROSIS |
CN113354581B (zh) * | 2020-03-06 | 2023-06-20 | 华南理工大学 | 手性氯喹及其磷酸盐的制备方法及其应用 |
WO2021217574A1 (en) * | 2020-04-30 | 2021-11-04 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Treatment or prevention of coronaviridae infection |
CN111551645B (zh) * | 2020-04-30 | 2022-11-08 | 上海中西三维药业有限公司 | 一种硫酸羟氯喹有关物质的检测方法及其应用 |
CN111909087A (zh) * | 2020-06-15 | 2020-11-10 | 珠海润都制药股份有限公司 | 一种手性氨基氯喹啉的制备方法 |
CN111662229B (zh) * | 2020-07-08 | 2023-03-24 | 精华制药集团南通有限公司 | 一种磷酸氯喹的制备工艺 |
CN111793026A (zh) * | 2020-07-23 | 2020-10-20 | 珠海润都制药股份有限公司 | 一种硫酸羟氯喹及其对映体的晶型和制备方法 |
CN114057640A (zh) * | 2020-08-05 | 2022-02-18 | 凯特立斯(深圳)科技有限公司 | 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法 |
CN112225697B (zh) * | 2020-10-16 | 2023-01-03 | 宁波大学 | 一种对映体纯氯喹及磷酸氯喹的制备方法 |
CN114573464A (zh) * | 2022-03-02 | 2022-06-03 | 重庆南松凯博生物制药有限公司 | 一种羟氯喹侧链精制方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4181725A (en) * | 1977-05-02 | 1980-01-01 | The Regents Of The University Of Michigan | Method for alleviating psoriasis |
WO1998017231A2 (en) | 1996-10-18 | 1998-04-30 | Charous B Lauren | Treatment and delivery of hydroxychloroquine |
JP2002543122A (ja) * | 1999-04-30 | 2002-12-17 | エイピーティー ファーマスーティカルズ エルエルスィー | 抗マラリア治療剤についての新規使用 |
US20060014786A1 (en) * | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
AU2003243409A1 (en) * | 2002-06-05 | 2003-12-22 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
US20040224876A1 (en) | 2003-02-14 | 2004-11-11 | Jost-Price Edward Roydon | Combination therapy for the treatment of immunoinflammatory disorders |
ZA200505996B (en) * | 2003-02-14 | 2006-12-27 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
AU2003219160A1 (en) * | 2003-03-12 | 2004-09-30 | Molecular Engines Laboratories Sa | Methods and compositions for the treatment of cancer |
TW200522932A (en) * | 2003-09-15 | 2005-07-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
DE602004018363D1 (de) | 2003-10-27 | 2009-01-22 | Vertex Pharma | Kombinationen für die hcv-behandlung |
SE0500055D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
CN101193622A (zh) | 2005-06-09 | 2008-06-04 | 比奥里波克斯公司 | 治疗炎性疾病的方法和组合物 |
PT1888033E (pt) * | 2005-06-09 | 2014-05-15 | Meda Ab | Método e composição para tratamento de distúrbios inflamatórios |
JP2009526070A (ja) | 2006-02-09 | 2009-07-16 | シェーリング コーポレイション | Hcvプロテアーゼ阻害薬とhcvポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法 |
US8895598B2 (en) | 2007-09-18 | 2014-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection |
US9101628B2 (en) * | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
WO2009045443A2 (en) * | 2007-10-02 | 2009-04-09 | The University Of Rochester | Methods and compositions related to synergistic responses to oncogenic mutations |
US20120114670A1 (en) | 2007-10-02 | 2012-05-10 | University Of Rochester | Methods and compositions related to synergistic responses to oncogenic mutations |
CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
CN102448458B (zh) | 2009-03-18 | 2015-07-22 | 小利兰·斯坦福大学理事会 | 治疗黄病毒科病毒感染的方法和组合物 |
EP3718405A1 (en) * | 2009-05-27 | 2020-10-07 | PTC Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
DK2460403T3 (da) | 2009-07-31 | 2019-08-19 | Smc Global Asset Inc | Steatohepatitis lever cancer model mus |
US9415046B2 (en) | 2009-09-29 | 2016-08-16 | Yale University | Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods |
EP2488180A4 (en) | 2009-10-12 | 2013-03-27 | Ipca Lab Ltd | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT / PROPHYLAXIS OF NON ALCOHOLIC HEPATIC STEATOSIS |
US9700560B2 (en) * | 2009-11-16 | 2017-07-11 | University Of Georgia Research Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
ES2869884T3 (es) * | 2011-09-16 | 2021-10-26 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico |
CA2864389A1 (en) | 2012-02-20 | 2013-08-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US20130273003A1 (en) * | 2012-04-17 | 2013-10-17 | Vertex Pharmaceuticals Incorporated | Therapies for Treating Hepatitis C Virus Infection |
AP3913A (en) | 2012-05-22 | 2016-11-26 | Idenix Pharamaceuticals Inc | D-amino acid compounds for liver disease |
TW201402556A (zh) | 2012-05-30 | 2014-01-16 | Toyama Chemical Co Ltd | 氘化含氮雜環羧醯胺衍生物或其鹽 |
US20140066469A1 (en) | 2012-08-21 | 2014-03-06 | Department Of Veterans Affairs | Treatment of diseases associated with inflammation |
JP6146990B2 (ja) | 2012-11-16 | 2017-06-14 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたcftr増強物質 |
CN103550242B (zh) | 2013-11-22 | 2015-07-15 | 四川国康药业有限公司 | 一种治疗肝纤维化的药物组合物及其制备方法 |
US10030044B2 (en) | 2013-11-27 | 2018-07-24 | Idenix Pharmaceuticals Llc | Nucleotides for the treatment of liver cancer |
JP6367545B2 (ja) | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
AU2016288699B2 (en) * | 2015-06-30 | 2020-11-26 | Eiger Group International, Inc. | Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions |
-
2016
- 2016-06-30 AU AU2016288699A patent/AU2016288699B2/en active Active
- 2016-06-30 TW TW112136665A patent/TW202402283A/zh unknown
- 2016-06-30 CA CA2989634A patent/CA2989634C/en active Active
- 2016-06-30 CN CN201680039155.3A patent/CN107922404B/zh active Active
- 2016-06-30 TW TW111123545A patent/TWI830262B/zh active
- 2016-06-30 WO PCT/US2016/040566 patent/WO2017004454A1/en active Application Filing
- 2016-06-30 IL IL310969A patent/IL310969A/en unknown
- 2016-06-30 KR KR1020187002620A patent/KR20180032578A/ko not_active IP Right Cessation
- 2016-06-30 IL IL300476A patent/IL300476B1/en unknown
- 2016-06-30 EP EP16818845.6A patent/EP3317274A4/en active Pending
- 2016-06-30 CA CA3178499A patent/CA3178499A1/en active Pending
- 2016-06-30 JP JP2017568408A patent/JP7068827B2/ja active Active
- 2016-06-30 US US15/738,827 patent/US10688083B2/en active Active
- 2016-06-30 KR KR1020237028986A patent/KR20230129590A/ko not_active Application Discontinuation
- 2016-06-30 CN CN202110651428.2A patent/CN113274386A/zh active Pending
- 2016-06-30 MX MX2017016681A patent/MX2017016681A/es unknown
- 2016-06-30 TW TW105120868A patent/TWI771272B/zh active
-
2017
- 2017-12-10 IL IL256233A patent/IL256233A/en active IP Right Grant
- 2017-12-13 ZA ZA2017/08471A patent/ZA201708471B/en unknown
- 2017-12-18 MX MX2023003792A patent/MX2023003792A/es unknown
- 2017-12-18 MX MX2022008100A patent/MX2022008100A/es unknown
-
2018
- 2018-07-11 HK HK18109030.3A patent/HK1249508A1/zh unknown
-
2020
- 2020-05-07 US US16/869,312 patent/US20210052553A1/en active Pending
- 2020-11-26 IL IL279020A patent/IL279020B2/en unknown
-
2021
- 2021-02-25 AU AU2021201234A patent/AU2021201234A1/en not_active Abandoned
-
2022
- 2022-05-02 JP JP2022075974A patent/JP7470151B2/ja active Active
-
2023
- 2023-03-07 AU AU2023201397A patent/AU2023201397A1/en active Pending
-
2024
- 2024-04-05 JP JP2024061358A patent/JP2024083475A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022008100A (es) | Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas. | |
MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MD3209381T2 (ro) | Compoziții care conțin tulpini bacteriene | |
MX2017004715A (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos. | |
MX2017011822A (es) | Anticuerpos anti-muc16 y sus usos. | |
EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
IL276808A (en) | Preparations and methods for the treatment of cancer | |
EA201692472A1 (ru) | Соединения для лечения рака мозга | |
SG10201809411PA (en) | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab | |
MX2022015250A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
MX2016013704A (es) | Conjugado farmaco-anticuerpo igf-1r y su uso para el tratamiento contra el cancer. | |
MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
SG11202001796SA (en) | Bacteria for targeting tumors and treating cancer | |
WO2017187343A3 (en) | Nanoemulsions and methods for cancer therapy | |
IL280830A (en) | Bracelets for use in cancer treatment methods | |
WO2017059122A8 (en) | Methods of treating and preventing amyotrophic lateral sclerosis | |
IL272147A (en) | Methods and preparations for the treatment of cancer | |
EP3781148A4 (en) | THERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER WITH 6,8-BIS-BENZYLTHIO-OCTONIC ACID | |
MX2019010060A (es) | Composiciones y metodo para tratar cancer. | |
IL280262A (en) | Compositions and methods for treating cancer | |
WO2016179529A3 (en) | Radiotherapeutic and companion imaging agents to target mc1r |